2.22
Schlusskurs vom Vortag:
$2.35
Offen:
$2.34
24-Stunden-Volumen:
3.06M
Relative Volume:
1.51
Marktkapitalisierung:
$175.80M
Einnahmen:
$32.31M
Nettoeinkommen (Verlust:
$-237.09M
KGV:
-0.7708
EPS:
-2.88
Netto-Cashflow:
$-219.11M
1W Leistung:
+12.69%
1M Leistung:
+35.37%
6M Leistung:
+69.47%
1J Leistung:
-55.95%
Editas Medicine Inc Stock (EDIT) Company Profile
Firmenname
Editas Medicine Inc
Sektor
Branche
Telefon
617-401-9000
Adresse
11 HURLEY ST., CAMBRIDGE, MA
Vergleichen Sie EDIT mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
EDIT
Editas Medicine Inc
|
2.22 | 175.80M | 32.31M | -237.09M | -219.11M | -2.88 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
440.87 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
509.72 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
309.70 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
542.15 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
247.08 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-28 | Eingeleitet | H.C. Wainwright | Buy |
2024-12-16 | Herabstufung | JP Morgan | Neutral → Underweight |
2024-12-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
2024-12-13 | Herabstufung | Stifel | Buy → Hold |
2024-12-13 | Herabstufung | Truist | Buy → Hold |
2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2024-11-25 | Herabstufung | BofA Securities | Buy → Underperform |
2024-11-06 | Hochstufung | Evercore ISI | In-line → Outperform |
2024-11-04 | Herabstufung | Raymond James | Outperform → Mkt Perform |
2024-08-08 | Hochstufung | BofA Securities | Neutral → Buy |
2024-05-09 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
2023-10-24 | Hochstufung | Citigroup | Neutral → Buy |
2023-10-18 | Hochstufung | JP Morgan | Underweight → Neutral |
2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
2023-09-29 | Hochstufung | Stifel | Hold → Buy |
2023-06-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
2022-12-13 | Eingeleitet | Citigroup | Neutral |
2022-12-06 | Fortgesetzt | Credit Suisse | Neutral |
2022-11-18 | Herabstufung | Credit Suisse | Outperform → Neutral |
2022-11-18 | Herabstufung | Oppenheimer | Outperform → Perform |
2022-09-29 | Eingeleitet | BofA Securities | Neutral |
2021-10-19 | Eingeleitet | SVB Leerink | Mkt Perform |
2021-09-24 | Eingeleitet | Stifel | Hold |
2021-09-10 | Hochstufung | Oppenheimer | Perform → Outperform |
2021-08-09 | Hochstufung | Truist | Hold → Buy |
2021-08-05 | Hochstufung | Evercore ISI | Underperform → Outperform |
2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
2021-04-16 | Eingeleitet | Goldman | Sell |
2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
2021-02-26 | Herabstufung | Truist | Buy → Hold |
2021-01-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
2021-01-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
2020-12-10 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2020-11-03 | Eingeleitet | Robert W. Baird | Underperform |
2020-06-18 | Fortgesetzt | SunTrust | Buy |
2020-02-21 | Eingeleitet | Wells Fargo | Equal Weight |
2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
2018-10-10 | Eingeleitet | Guggenheim | Neutral |
2018-09-21 | Eingeleitet | Raymond James | Outperform |
2018-05-15 | Bestätigt | Chardan Capital Markets | Buy |
2018-02-13 | Eingeleitet | CLSA | Underperform |
2018-01-23 | Hochstufung | SunTrust | Hold → Buy |
2017-07-14 | Eingeleitet | SunTrust | Hold |
2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
2016-08-10 | Hochstufung | Jefferies | Hold → Buy |
2016-06-02 | Eingeleitet | Jefferies | Hold |
2016-02-29 | Eingeleitet | JMP Securities | Mkt Outperform |
2016-02-29 | Eingeleitet | JP Morgan | Neutral |
2016-02-29 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Editas Medicine Inc Aktie (EDIT) Neueste Nachrichten
Cancer Gene Therapy Market Set to Soar: Breakthrough - openPR.com
From Now to 2032: Unpacking the Genome Editing Market's - openPR.com
Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - AOL.com
Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool
Analysts Set Editas Medicine, Inc. (NASDAQ:EDIT) Price Target at $5.36 - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) Position Trimmed by Bank of America Corp DE - MarketBeat
Analysts Offer Predictions for Editas Medicine FY2026 Earnings - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Editas Medicine (EDIT) Unveils Promising Gene Editing Data for B - GuruFocus
Kalkine: Editas Medicine’s In Vivo Gene Editing Progress Unveiled at EHA 2025 with tLNP Approach - Kalkine Media
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle - GuruFocus
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hema - GuruFocus
Editas Medicine Reports 58% HBG1/2 Promoter Editing in Non-Human Primates Using High Efficiency tLNP Delivery Method - Nasdaq
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June - The Manila Times
Breakthrough: New Gene Editing Therapy Achieves 58% Success Rate for Sickle Cell Disease Treatment - Stock Titan
Why Is Editas (EDIT) Up 40% Since Last Earnings Report? - Yahoo Finance
Ameriprise Financial Inc. Has $289,000 Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) CEO Sells $26,130.24 in Stock - MarketBeat
Zacks Research Raises Earnings Estimates for Editas Medicine - MarketBeat
Two Sigma Investments LP Increases Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Millennium Management LLC Has $3.49 Million Stock Position in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) Short Interest Down 21.7% in May - MarketBeat
editas medicine amends stock plan and increases authorized shares - Investing.com
Editas Medicine Stockholders Approve Key Amendments - TipRanks
editas medicine amends stock plan and increases authorized shares By Investing.com - Investing.com India
Two Sigma Advisers LP Increases Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Top 5 CRISPR Companies To Invest In (June 2025) - Securities.io
Millennium Management LLC Cuts Stock Position in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World
Editas Medicine, Inc. (NASDAQ:EDIT) Shares Purchased by BNP Paribas Financial Markets - Defense World
Northern Trust Corp Has $884,000 Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World
Brokerages Set Editas Medicine, Inc. (NASDAQ:EDIT) Price Target at $5.36 - MarketBeat
Editas Medicine (EDIT) Joins Russell Microcap Index - GuruFocus
Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit - Seeking Alpha
CRISPR and Cas Genes Market Set to Witness Significant Growth - openPR.com
Editas Medicine’s SWOT analysis: gene editing stock pivots amid challenges By Investing.com - Investing.com Canada
Editas Medicine’s SWOT analysis: gene editing stock pivots amid challenges - Investing.com Australia
1 Stock Down 97% That Could Double, According to Wall Street - AOL.com
Tang Capital Management LLC Purchases Shares of 400,000 Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) Given Consensus Rating of “Hold” by Brokerages - Defense World
Jacobs Levy Equity Management Inc. Has $900,000 Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Editas Medicine, Inc.'s (NASDAQ:EDIT) Price Is Right But Growth Is Lacking After Shares Rocket 28% - simplywall.st
Finanzdaten der Editas Medicine Inc-Aktie (EDIT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Editas Medicine Inc-Aktie (EDIT) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER |
Jun 03 '25 |
Sale |
1.72 |
726 |
1,252 |
69,519 |
O'Neill Gilmore Neil | CEO |
Jun 03 '25 |
Sale |
1.72 |
15,192 |
26,196 |
280,282 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):